Article Sidebar

PDF
Date Published: 17/03/2023
Abstract Views: 243
Views PDF: 98
DOI: https://doi.org/10.51298/vmj.v524i1A.4625
Issue
Vol. 524 No. 1A (2023)
Section
Các bài báo
How to Cite
Lê, T. Đức ., & Phạm , T. D. . (2023). SURVIVAL RESULTS AND ASSOCIATED FACTORS OF PACLITAXEL REGIMEN CHEMOTHERAPY IN RECURRENT OR METASTATIC BREAST CANCER. Vietnam Medical Journal, 524(1A). https://doi.org/10.51298/vmj.v524i1A.4625

SURVIVAL RESULTS AND ASSOCIATED FACTORS OF PACLITAXEL REGIMEN CHEMOTHERAPY IN RECURRENT OR METASTATIC BREAST CANCER

Thanh Đức Lê1,, Thị Dịu Phạm 2
1 National cancer hospital
2 Hai Duong Medical technical University

Main Article Content

Abstract

Objectives: Our study aimed to evaluated survival results and associated factors of paclitaxel regimen chemotherapy in recurrent or metastatic breast cancer. Patients and methods: Retrospective, descriptive study on 47 patients with recurrent or metastatic of breast cancer, who were treated with paclitaxel chemotherapy regimen at National Cancer Hospital from 01/2017 to 01/2022. Results: The mean age of patients was 53.8 years old. The most common metastatic lesions were bone, lung, lymph node (mediastinal lymph node, abdominal lymph node, contralateral supraclavicular node) and liver accounting for 55.3%, 34.0%, 27.7% and 27.7%, respectively. 31 patients received the first-line regimen, accounting for 66.0%, and 16 patients received the second-line regimen, accounting for 34.0%. Median progression-free survival was 7.0 months (95% CI: 5,7-8.3). Median overall survival was 17.0 months (95% CI: 13.4-20.6). Patients with visceral metastases or patients treated in second-line regimen had a worse prognosis than patients without visceral metastases or patients receiving the first-line regimen. Conclusion: Paclitaxel regimen chemotherapy is effective in high survival time for recurrent or metastatic breast cancer with a median progression-free survival of 7.0 months and overall survival of 17.0 months.

Article Details

Keywords

metastatic breast cancer, paclitaxel, survival time.

References

1. Sung H., Ferlay J., Siegel R.L. và cộng sự. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3), 209–249.
2. van Maaren M.C., de Munck L., Strobbe L.J.A. và cộng sự. (2019). Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer, 144(2), 263–272.
3. Mátrai Z. và Rényi Vámos F. (2014). [Surgical possibilities in the treatment of advanced and locally recurrent breast cancers]. Orv Hetil, 155(37), 1461–1468.
4. Conlin A.K. và Seidman A.D. (2007). Taxanes in breast cancer: an update. Curr Oncol Rep, 9(1), 22–30.
5. Jones S.E., Erban J., Overmoyer B. và cộng sự. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol, 23(24), 5542–5551.
6. Sledge G.W., Neuberg D., Bernardo P. và cộng sự. (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol Off J Am Soc Clin Oncol, 21(4), 588–592.
7. Bishop J.F., Dewar J., Toner G.C. và cộng sự. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol, 17(8), 2355–2364.
8. Kellokumpu-Lehtinen P, Tuunanen T, Asola R, et al. Weeklye Paclitaxel – An Effective Treatment for Advanc d Breast Cancer. Anticancer Res. 2013;33(6):2623-2627.
9. Perez, E. A., C. L. Vogel, D. H. Irwin, et al. 2001. "Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer." J.Clin Oncol. 19(22):4216-4223.